z-logo
Premium
Population pharmacokinetics of intravenous valproic acid in Korean patients
Author(s) -
Park H.M.,
Kang S.S.,
Lee Y.B.,
Shin D.J.,
Kim O.N.,
Lee S.B.,
Yim D.S.
Publication year - 2002
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1046/j.1365-2710.2002.00440.x
Subject(s) - valproic acid , nonmem , pharmacokinetics , population pharmacokinetics , medicine , volume of distribution , population , body mass index , therapeutic drug monitoring , pharmacology , epilepsy , psychiatry , environmental health
Summary Objective:  To determine population‐based pharmacokinetic parameters for intravenous valproic acid, and the factors influencing these parameters, in Korean adults. Methods:  Valproic acid concentrations were obtained using a peak and trough sampling scheme for 102 Korean epileptic patients who were not taking concurrent antiepileptic medication. Three hundred and fifty‐four serum concentrations were analysed according to a one‐compartment model with a mixed effect modelling method (NONMEM Ver 5·0). The influence of body‐weight (kg), height, daily valproic acid dose (mg/day), body mass index (kg/m 2 ), sex, and age on volume of distribution (Vd) and clearance (CL) was assessed in the course of analysis. Results:  Vd and CL of valproic acid increased with body‐weight. No significant influence of the other screened covariates was observed. The final regression model was:Interindividual variabilities (coefficient of variation) for CL and Vd were 32 and 18%, respectively. Residual error including intraindividual variability was 26·7%. Conclusion:  The current results may be used as a basic reference to optimize drug therapy with intravenous valproic acid. Further research on the paediatric population is necessary to confirm the non‐linearity of the relation between body‐weight and Vd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here